Big News Gains: Uni-Pixel (NASDAQ:UNXL), Simulations Plus (NASDAQ:SLP), Navistar International Corporation (NYSE:NAV), Regulus Therapeutics (NASDAQ:RGLS), Oncothyreon Inc (NASDAQ:ONTY)

UniPixel, Inc. (NASDAQ: UNXL), announced shipment of touch screen sensor engineering samples to be assembled into touch panels by a new touch panel integration partner that will be delivered to a prospective new Asia-based Tier 1 PC OEM customer for evaluation in a new 13.3″ notebook PC. The engineering samples feature UniPixel’s XTouch touch sensor technology with its new hybrid-metal plating process and Diamond Guard resin coating. The hybrid-metal plating further improves the visual appearance of the XTouch sensors, and is expected to further enhance robustness of the sensor under extreme environmental stress conditions.
UniPixel, Inc. (NASDAQ: UNXL) develops and markets Performance Engineered Films for the touch screen and flexible electronics markets. The company’s roll-to-roll electronics manufacturing process patterns fine line conductive elements on thin films. The company markets its technologies for touch panel sensor, cover glass replacement, and protective cover film applications under the XTouch™ and Diamond Guard™ brands.
Uni-Pixel, Inc. (NASDAQ:UNXL) shares advanced 7.55% in last trading session and ended the day at $1.14. UNXL has a return on assets of -100.90%. Uni-Pixel, Inc. (NASDAQ:UNXL) quarterly performance is -62.25%.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide.
Simulations Plus, Inc. (NASDAQ:SLP) caters to the Technology space. It has a net profit margin of 21.70% and weekly performance is 12.25%. On the last day of trading company shares ended up $7.30. Simulations Plus, Inc. (NASDAQ:SLP) distance from 50-day simple moving average (SMA50) is 13.96%.

Simulations Plus, Inc. (NASDAQ: SLP), announced that it had been notified by the U.S. Food and Drug Administration (FDA) that the company has been awarded a second cooperative agreement for $200,000 per year for up to three years. This award is in addition to the similar project the company was awarded last year, and which was recently renewed for the second year. This new project is for the development of PBPK simulation for long-acting injectable microspheres.

On 03 September, Navistar International Corporation (NYSE:NAV) shares moved up 12.82% and was closed at $18.74. NAV EPS growth in last 5 year was -30.90%. Navistar International Corporation (NYSE:NAV) year to date (YTD) performance is -44.03%.

Truck maker Navistar International Corporation (NYSE:NAV) said it and former Chief Executive Dan Ustian face potential penalties by the U.S. Securities and Exchange Commission over past accounting and disclosure matters. Navistar was notified last month that SEC staff recommended an “enforcement action” that may include penalties in connection with alleged securities violations, it said in a securities filing on Wednesday.
Navistar International Corporation manufactures and sells commercial and military trucks, diesel engines, and school and commercial buses; and provides service parts for trucks and diesel engines worldwide.

On Aug. 25, Regulus Therapeutics Inc. (NASDAQ:RGLS), announced the appointment of Michael Huang, M.D. as Vice President, Clinical Development. Dr. Huang is an experienced drug developer with proven success in advancing programs through clinical trials that led to commercialization in a wide range of therapeutic areas.
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field.
Regulus Therapeutics Inc. (NASDAQ:RGLS) shares fell -8.55% in last trading session and ended the day at $8.45. RGLS has a return on assets of -45.70%. Regulus Therapeutics Inc. (NASDAQ:RGLS) quarterly performance is -20.21%.

Oncothyreon is a clinical-stage biopharmaceutical company specializing in the development of innovative therapeutic products for the treatment of cancer. Our goal is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients.
Oncothyreon Inc (NASDAQ:ONTY) caters to the Healthcare space. Its weekly performance is -5.10%. On the last day of trading company shares ended up $3.35. Oncothyreon Inc (NASDAQ:ONTY) distance from 50-day simple moving average (SMA50) is -4.44%.

Oncothyreon Inc. (NASDAQ:ONTY) announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, Sept. 9, 2015 at 9:10 a.m. Eastern Time in New York.